BioSpace News Archive

Treatment with a short course of T-Guard was generally well tolerated with no significant infusion reactions.

The gross proceeds to Viking from this offering are approximately $14.8M, before deducting underwriting discounts and commissions and other estimated offering expenses.

Revance announced the closing of an underwritten public offering of 6,139,515 shares of its common stock at a price to the public of $31.00 per share.

The approval was based on the INTREPID study, the first multi-center, prospective, double-blind, randomized sham-controlled study of DBS for PD in the U.S.

Janssen R&D today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX had a manageable safety profile and a 12 percent rate of infusion reactions in patients with relapsed or refractory multiple myeloma.

City of Hope patients whose acute myeloid leukemia (AML) was no longer responding to standard therapies and a patient with a rare blood cancer, blastic plasmacytoid dendritic cell neoplasm, achieved a complete response (cancer-free) after undergoing treatment with MB-102 CAR-T therapy, which targets CD123 cells.

Preliminary exploratory efficacy results from an ongoing phase 1 dose escalation study showed that an overall response rate of 58.8 percent was observed with single agent DS-3201 in 17 evaluable patients with NHLs, including B-cell and T-cell lymphomas, who were relapsed from or refractory to standard treatment or for whom no standard treatment was available.

The results of these trials have been published in leading peer-reviewed journals.

ESSA Pharma today reported financial results for the fourth quarter and year ended September 30, 2017 and progress on its preclinical development program.